The genome of equine infectious anemia virus (EIAV) contains several small open reading frames (ORFs), the importance of which in the development of the virus is not clear. We investigated the possibility that the largest of these ORFs (ORF S3) is expressed during the course of the viral infection. The ORF S3 information was expressed in Escherichia coli, and the antigen was used to raise monospecific antiserum. A 20-kDa protein expressed in cells producing EIAV was identified as the gene product of ORF S3. Furthermore, sera from EUIV-infected animals specifically recognized this protein, indicating that the ORF S3 antigen is expressed in vivo as well. A model for the expression of this new viral antigen is presented. The proposed splicing pattern is similar to that of the VEP-1 protein of maedi-visna virus, which tempts us to speculate that ORF S3 defines the second exon of the EIAV Rev protein.
Like other members of the lentivirus subfamily, equine infectious anemia virus (EIAV) contains in addition to the structural retroviral genes gag, pol, and env (3, 28) several small open reading frames (ORFs), the expression of which has not been demonstrated directly (14, 23) . For the human immunodeficiency virus (HIV), it has been demonstrated that several small regulatory proteins involved in the control of the viral life cycle are encoded in small ORFs and are expressed from multiple spliced messenger RNAs (9, 26) . One of these regulatory proteins is the HIV transactivator of transcription (Tat), the first coding exon of which is situated in front of the envelope gene and the second coding exon of which is localized in the carboxy-terminal part of the envelope transmembrane region and read in a different reading frame (9) . Another HIV-regulatory protein (Rev) is also expressed from two coding exons, both localized in the same areas as the Tat exons (26) .
Recently, it has been demonstrated that a region downstream of pol and overlapping the start of the env gene of EIAV and containing the small ORFs ORF Si and ORF S2 is necessary for transactivation of the autologous promoter (7, 25) . Furthermore, inspection of the published sequence data on the EIAV proviral genome allows the identification of a third ORF (ORF S3) capable of encoding 135 amino acids (14, 23) . This coding sequence is completely contained within the gene encoding the transmembrane protein of EIAV. This localization is similar to the one described for the second coding exons of both tat and rev genes of HIV type 1 (HIV-1) and HIV-2.
The HIV-1 nef gene, on the other hand, is localized beyond the envelope-coding region, whereas for HIV-2, the nef equivalent overlaps the carboxy terminus of the transmembrane protein and extends into the 3' long terminal repeat (12, 29) .
In this study, we expressed the ORF S3 information of EIAV in Escherichia coli, and antibodies were raised to the purified protein. (14) . An ApaI-XbaI fragment, containing almost all the ORF S3 information (Fig. 1A) , was subcloned into the bacterial expression vector pEX (27) . The pEX vectors are designed to allow the cloned information to be fused carboxy terminal to ,-galactosidase to yield a recombinant fusion protein that can be easily detected in Coomassie blue-stained gels after electrophoretic separation of the total cellular extract. Expression of the cloned information is controlled by the lambda rightward promoter. Transcription can be regulated by the c1857 repressor, provided from a compatible plasmid (21) . This repressor ts mutant is active at 28°C but can be inactivated by shifting the culture to 42°C (induction). All inductions were done over a period of 3 h, and culture aliquots (1 ml) were removed every hour.
Cells were pelleted and lysed by boiling in sodium dodecyl sulfate-containing sample buffer (50 mM Tris hydrochloride [pH 7.5], 2% sodium dodecyl sulfate, 5% ,-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue), and the supernatant was fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
The gels were either stained for protein or used for Western immunoblot transfer by using the conditions described by Dunn (8) . From these preliminary experiments, it was already clear that some sera from EIAV-infected horses react with the ,-galactosidase fusion protein, whereas no reaction was obtained with ,-galactosidase (not shown).
To investigate this in more detail and to eliminate all cross-reaction with the ,-galactosidase moiety, we expressed the ORF S3 protein in a vector of the pIGAL series (Fig. 1B) Western blot strips were incubated with the preimmune sera (lanes 1 and 3) or with the antisera (lanes 2 and 4) and developed with an anti-rabbit alkaline phosphatase conjugate. Calibration of both gels is indicated in kilodaltons.
information was transferred from the pEX vector to the pIGAL-10 vector as an EcoRI-StuI fragment. This construction should produce a fusion protein of 21,214 Da, referred to as ORF S35. To verify the reading frame fusion, the nucleotide sequence of the ORF S35 expression plasmid was determined in the gene fusion region by using the dideoxy chain termination method. The sequence was found to be in complete agreement with the one predicted to yield a CroLacI-ORF S3 fusion protein. Since the ORF S3 is completely contained within the gene fragment coding for the carboxyterminal part of the transmembrane protein, expression of the overlapping part of the envelope information was achieved by introducing the same gene fragment into the appropriate reading frame of the pIGAL vector (pIGALl). The resulting plasmid was termed pEIAV-TM1.
Both plasmids were induced for expression in E. coli SG4044 (10) , and cell extracts were analyzed by Western blotting (Fig. 1C) Fig. 4 , amino acids 15 to 28) was also investigated.
From Fig. 1D it is obvious that the sera obtained from both rabbits recognize the ORF S35 protein in the Western blot, whereas the preimmune serum does not. The ORF S35 protein is often revealed as a doublet (see also Fig. 3) (5 ,lI) , and the immune complexes were collected with protein A-Sepharose 4B beads (Pharmacia) (13) and separated on a 15% sodium dodecyl sulfate-polyacrylamide gel (15) . Gels were subsequently processed for fluorography (Amplify; Amersham) and exposed at -70°C (Fuji X-ray film) for 24 The results shown in Fig. 2 indicate that in the immunoprecipitation reaction ( Fig. 2A and B) as well as in the Western blot analysis (Fig. 2C) , a protein of 18 to 20 kDa (depending on the way it is determined) is revealed in infected cells but not in control cells. This indicates that ORF S3 protein is expressed in these EIAV-infected cells.
Analysis of sera from EIAV-infected animals. To evaluate whether the ORF S3 protein is antigenic in vivo, several serum samples from EIAV-infected animals and normal control sera were tested for reactivity with the E. coliproduced protein. All sera were preincubated with extract made from induced E. coli SG4044 cells containing a-plasmid vector without any EIAV information. The cells were concentrated from the induced culture by centrifugation, resuspended in 1/10 of the original volume, and lysed by sonication. The soluble fraction was used for incubation with an equal volume of each serum at room temperature for 1 h.
The mixture was then further diluted 50-fold in TBS (10 mM Tris hydrochloride, pH 7.5, containing 150 mM NaCl and 0.1% bovine serum albumin), and Western blot strips containing extract from the ORF S35-producing bacteria were incubated with this reagent for 2 h at room temperature with constant agitation.
The strips were washed with TBS (3 times for 10 min each) and incubated with an anti-horse immunoglobulin G conjugated to alkaline phosphatase (Jackson Immunoresearch). After three more washings, the strips were developed as described above. Figure 3 shows some representative strips developed with EIAV-positive horse sera. Of the 40 serum samples from EIAV-infected horses tested, 6 (15%) were found to react with the ORF S3 protein, whereas 29 (72%) were positive for the EIAV Gag precursor (p55) expressed in the same configuration (data not shown). The typical ORF S35 reaction was not seen when extracts from noninduced E. coli cultures or when extracts from induced cultures not containing EIAV information were used. Sera from noninfected animals did not react with the ORF S35 fusion protein either (11 serum samples; data not shown). All sera that reacted with ORF S35 also reacted with the EIAV Gag precursor. These results show that in some animals, an immune response toward the ORF S3 protein is mounted upon infection with EIAV.
The data indicate that this protein is produced in infected animals but that not all animals have detectable levels of antibodies to it. This is comparable with data obtained with some nonstructural HIV antigens, for which antibodies can be detected only in some patients with the acquired immune deficiency syndrome (1, 2) . The data presented in this paper demonstrate that the ORF S3 represents a novel retroviral gene of EIAV which is expressed in infected animals as well as in persistently infected cells. Since ORF S3 does not contain a regular initiation codon, it is most probable that expression is achieved from a spliced mRNA, although initiation at other codons has also been described (4) .
Since the size of the protein immunoprecipitated from the EIAV-infected cells is comparable to the calculated size for the ORF S3 protein, we hypothesize that only a small part of the protein would be coded for by the (5, 17, 24) .
By analogy with these other lentivirus examples, it is tempting to speculate that the ORF S3 of EIAV is spliced to the small ORF (ORF S2) which has been described previously (23) and which is located in front of the envelope gene (Fig. 1A) . Since the ORF S2 contains an initiation codon (second codon) and a consensus splice donor site (CCCAG/ GGGAAT, bp 5341 to 5351), it can be spliced to a splice acceptor site, situated in the ORF S3 sequence (TCCTC AG/G, bp 7235 to 7242) (18) . Base pair positions are defined as described previously (14) .
This would give rise to a protein of 152 amino acids (17, 657 Da) , in reasonable agreement with the value estimated from our polyacrylamide gel electrophoresis analysis (Fig. 2) .
The hydrophilicity profile of the ORF S3 protein does not contain marked hydrophobic regions (Hopp and Woods algorithm) (Fig. 4) . This is analogous to what has been described for the VEP-1 protein of maedi-visna virus (17) and is in contrast to the profile for the Nef protein of HIV-1 obtained by using the same algorithm.
Moreover, the ORF S3 protein does contain basic stretches of sequences that might function as nuclear location signals (amino acids 129 to 133, KRRRK, and amino acids 46 to 49, RRDR), as has been described for the visna virus VEP-1 protein (17) and for the HIV-1 Tat protein (11, 22) , as well as for the simian immunodeficiency virus Gag precursor (6) .
In conclusion, we have shown that EIAV encodes a novel retroviral protein which is expressed during the viral life cycle in vivo as well as in infected cell cultures. The calculated molecular mass of the deduced protein (Fig. 4) approximates the 18 regulation of splicing (equivalent to HIV Rev) (24; R. Vigne, nicity and its in vivo expression. It will be important to I. Gourdou, V. Mazarin, G. Querat, N. Sauze, G. Audoly, determine whether the in vivo expression affects the viral and P. Filippi, Proc. 21st Congr. Int. Assoc. Biol. Standardpathogenesis of EIAV infection and whether the presence of ization, in press). If the splicing pattern described here for antibodies influences the clinical manifestation of the disease ORF S3 is correct, this might imply that the ORF S3 protein in horses. could encode the second exon of the EIAV Rev protein. 64, 1990 
